Experienced in Synovial Sarcoma

Sebastian F. Michels

Kerpener Str. 62, 
Koeln, NW, DE 
Experienced in Synovial Sarcoma
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Sebastian Michels practices in Koeln, Germany. Mr. Michels is rated as an Experienced expert by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Synovial Sarcoma.

Gender
Male

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany
Other Locations
Kerpener Str. 62, Koeln, NW 50931, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
Enrollment Status: Terminated
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
View 1 Less Clinical Trial

50 Total Publications

Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Michels's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile